Insulin Secretion & Hypoglycemia Differential

Islet architecture and glucose-stimulated insulin secretion

Islet cells. β cells, which secrete insulin (together with C-peptide and amylin), are the most numerous islet cells and classically occupy the core; α cells (glucagon) and δ cells (somatostatin) sit at the rim, with smaller populations of PP cells. The cells regulate one another: insulin from β cells restrains glucagon release, and δ-cell somatostatin inhibits both α and β cells. In type 1 diabetes, loss of the intra-islet insulin signal blunts the glucagon response to hypoglycemia within the first few years.

The glucose sensor. GLUT2 lets glucose equilibrate across the β-cell membrane. Glucokinase (hexokinase IV) has a high Km of about 8 mM and is not inhibited by glucose-6-phosphate, so it phosphorylates glucose at a rate proportional to blood glucose, and glycolytic flux and ATP generation track glycemia. Heterozygous inactivating GCK mutations raise the glucose set point (GCK-MODY), whereas activating mutations cause hyperinsulinemic hypoglycemia.

Biphasic release. Glucose provokes a brisk first phase from docked granules within minutes, followed by a sustained second phase; loss of first-phase release is an early defect in type 2 diabetes.

Drugs, incretins and proinsulin processing

K_ATP drugs. Sulfonylureas (glipizide, glyburide, glimepiride) and meglitinides (repaglinide, nateglinide) bind SUR1 and close K_ATP, so insulin is released even when glucose is low, causing hypoglycemia and weight gain. Diazoxide does the opposite: it holds K_ATP open and hyperpolarizes the β cell, reducing insulin secretion. It is used for inoperable insulinoma and for congenital hyperinsulinism when the channel is functional; its side effects include hypertrichosis and sodium and fluid retention.

The incretin effect. Oral glucose releases far more insulin than an intravenous load producing the same plasma glucose. The difference is GLP-1 from L cells of the ileum and colon and GIP from K cells of the duodenum and proximal jejunum, which act through Gs-coupled receptors and cAMP to amplify glucose-dependent secretion; incretins account for roughly 50–70% of the insulin response to a meal. DPP-4 inactivates both within minutes. Because incretin action requires glucose, GLP-1 agonists and DPP-4 inhibitors alone rarely cause hypoglycemia.

Other signals. Amino acids (arginine, leucine), vagal acetylcholine acting on M3 receptors during the cephalic phase, incretins and β2-agonists stimulate insulin release. α2-adrenergic signaling from catecholamines and somatostatin inhibit it, which is why insulin falls during stress and exercise.

Proinsulin and C-peptide. Preproinsulin loses its signal peptide in the rough ER, folds as proinsulin with disulfide bonds linking the A and B chains, and is cleaved in secretory granules by prohormone convertases and carboxypeptidase E. Insulin and C-peptide are therefore released in equimolar amounts, with a small fraction of intact proinsulin. The liver extracts about half of portal insulin on first pass, and insulin's half-life is about 5 minutes; C-peptide is not extracted by the liver and lasts about 30 minutes, which makes it the best measure of endogenous secretion. The kidneys clear C-peptide, so levels are high in renal failure.

Counter-regulation and symptoms

Two symptom families. Neurogenic (autonomic) symptoms come from sympathoadrenal discharge: adrenergic tremor, palpitations and anxiety, plus cholinergic sweating, hunger and paresthesias. Neuroglycopenic symptoms reflect the brain's dependence on a continuous glucose supply: confusion, behavior change, focal deficits, seizures and coma. Because sweating is carried by sympathetic cholinergic fibers, it persists on β-blockers, which blunt tremor and palpitations.

Hypoglycemia unawareness. Recurrent hypoglycemia lowers the glucose level that triggers sympathoadrenal responses (hypoglycemia-associated autonomic failure), so neuroglycopenia arrives before any warning. In long-standing type 1 diabetes the glucagon response is already gone, and a blunted epinephrine response leaves little defense. Scrupulous avoidance of hypoglycemia for 2–3 weeks can restore awareness.

Evaluating fasting hypoglycemia

Whipple triad first. Hypoglycemia is established by symptoms, a documented low plasma glucose (below 55 mg/dL in a nondiabetic adult) and relief when glucose is raised. The workup is done during a spontaneous episode or a supervised 72-hour fast, drawing glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate and an oral-hypoglycemic screen at the low point. A glucose rise of at least 25 mg/dL after 1 mg of IV glucagon at the end of the fast shows that insulin (or IGF-2) was holding glycogen in the liver.

Insulinoma. The most common functional pancreatic neuroendocrine tumor is about 90% benign and solitary and usually smaller than 2 cm. Patients have fasting or exertional neuroglycopenia and often gain weight from eating to prevent symptoms; a minority have MEN1, often with multiple tumors. Treatment is surgical resection (often enucleation); diazoxide controls hypoglycemia when surgery is not possible.

Oral secretagogues. Sulfonylureas and meglitinides force endogenous secretion, so insulin, C-peptide and proinsulin rise exactly as in insulinoma, and only a positive drug screen separates them. Causes include surreptitious use, dispensing errors and accidental ingestion by children. After overdose, octreotide suppresses further insulin release and prevents recurrent hypoglycemia.

Exogenous insulin. Injected insulin suppresses the patient's own β cells, so insulin is high while C-peptide and proinsulin are low. Factitious hypoglycemia is classically seen in health-care workers and relatives of people with diabetes; an insulin overdose in a diabetic patient gives the same pattern.

Autoimmune insulin syndrome (Hirata disease). Autoantibodies against insulin itself bind secreted insulin and release it unpredictably, producing postprandial hyperglycemia followed by late hypoglycemia, with very high total insulin, elevated C-peptide and proinsulin, and positive insulin antibodies. It is linked to sulfhydryl-containing drugs such as methimazole and α-lipoic acid and to HLA-DR4, and most cases are reported in East Asians. In type B insulin resistance, by contrast, the antibodies target the insulin receptor.

Non-islet cell tumor hypoglycemia. Large mesenchymal tumors, such as solitary fibrous tumors, and hepatocellular carcinoma secrete incompletely processed "big" IGF-2, which activates insulin receptors. Insulin, C-peptide, proinsulin and ketones are all suppressed, GH and IGF-1 are low, and the IGF-2:IGF-1 ratio exceeds 10.

Hypoglycemia without excess insulin. Ethanol oxidation raises the NADH/NAD+ ratio, diverting pyruvate to lactate and oxaloacetate to malate; once fasting has depleted glycogen, gluconeogenesis cannot keep up, so the fasting binge drinker becomes hypoglycemic. Adrenal insufficiency removes cortisol support for gluconeogenesis; severe liver failure removes glycogen stores and gluconeogenesis; renal failure reduces renal gluconeogenesis and insulin clearance and lets drugs accumulate; and sepsis increases glucose use while impairing production. In all of these, insulin and C-peptide are appropriately suppressed.

Neonatal hyperinsulinism

Infant of a diabetic mother. Maternal glucose crosses the placenta but insulin does not, so fetal hyperglycemia induces β-cell hyperplasia and hyperinsulinemia, and insulin acting as a growth factor causes macrosomia. When the cord is clamped the glucose supply stops but hyperinsulinism persists, and hypoglycemia develops within the first hours of life.

Congenital hyperinsulinism. This is the most common cause of persistent hypoglycemia in infancy and usually results from loss-of-function mutations of ABCC8 (SUR1) or KCNJ11 (Kir6.2). The channel stays closed, the β cell stays depolarized, and insulin is secreted regardless of glucose, so affected infants need high glucose infusion rates and have low ketones. Diazoxide usually fails because it needs a working channel; octreotide or pancreatectomy is used, and focal lesions, localized by 18F-DOPA PET, can be cured by limited resection. Gain-of-function mutations of the same genes cause the opposite disorder, neonatal diabetes, which responds to sulfonylureas.

Hypoglycemia with low ketones and a glycemic response to glucagon signals an insulin-like effect (insulin, a secretagogue, or IGF-2); hypoglycemia with high ketones points to fasting, alcohol or counter-regulatory hormone deficiency.